ArticleFrontiers in oncology2026
Modality-level attribution and redundancy-aware radiomics for MRI-based differentiation of melanoma and NSCLC brain metastases.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Differentiating the primary source of brain metastases using imaging alone is difficult, especially when intracranial disease is the initial sign of cancer. This study aimed to develop and validate a redundancy-aware, explainable radiomics framework for distinguishing melanoma from non-small cell lung cancer (NSCLC) brain metastases through multiparametric MRI. Methods: Lesion-level radiomic features were extracted from T1, contrast-enhanced T1 (T1CE), T2, and FLAIR sequences. Correlation-based redundancy filtering and L1-regularized feature ranking were applied to minimize collinearity among features. A structured parametric analysis across progressively larger top-K feature subsets was performed to evaluate performance stability and modality-specific contribution patterns. Multiple machine learning classifiers were tested using cross-validation and an independent test set, with model interpretability assessed via TreeSHAP to quantify feature- and modality-level contributions. Results: The best-performing configuration achieved a test AUC of 0.75, while RF-200 was selected for the primary tree-based explainability analysis due to its stable AUC-based discrimination. SHAP analysis showed that classification depended on a small set of predictors combining texture and intensity distribution features. FLAIR and T2 features contributed most to model attribution, suggesting that fluid-sensitive sequences capture discrimination-relevant heterogeneity and microenvironmental signals beyond contrast enhancement. Discussion: A redundancy-aware, interpretable radiomics approach shows promising preliminary discrimination between melanoma and NSCLC brain metastases and provides structured insight into modality-specific sequence contributions. External validation and prospective reader studies are required before clinical translation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.